A $20bn industry by 2024? AI for drug discovery will be driven by biopharma and the rise of Asian tigers, says Insilico CEO 17-Apr-2019 By Melissa Fassbender China-based pharmaceutical companies betting big and small biopharma able to quickly innovate will drive the use of AI for drug discovery – a market some analysts predict will reach a valuation of $20bn by 2024.
Gilead doubles down on NASH with two deals in one week 16-Apr-2019 By Ben Hargreaves Gilead arranges partnerships with insitro and Novo Nordisk to develop new options for patients with NASH.